Seemingly confident in the level of similarity between Sandoz Inc.'s Zarxio and Amgen Inc.'s Neupogen, the FDA has one voting question for the Oncologic Drugs Advisory Committee (ODAC) that will weigh in Wednesday on what is likely to be the first U.S. biosimilar.